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Introduction
Intractable chronic neck pain after a whiplash trauma
is a major burden for patients, healthcare providers
and insurance companies. It is estimated that 14–42%
of patients develop chronic symptoms after an acute
whiplash trauma [2].
These patients often have reduced mobility of
the neck with tender muscles and increased muscle
activity [25]. Pathophysiology is still unknown, but
myofascial triggerpoints can develop in cervical
muscles from excessive neck and shoulder muscle
contraction due to an overt injury such as accelera-
tion of the neck in a motor vehicle accident [5]. Bo-
tulinum toxin is used to treat a variety of neurological
disorders associated with pathologically increased
muscle tone.
Two previous studies have reported that botulinum
toxin might be successful in patients with chronic
neck pain following whiplash injuries [6, 12]. These
studies were uncontrolled and the follow-up period
was relatively short. In a randomized placebo-
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j Abstract Objectives Neck pain
in chronic whiplash syndrome is a
major burden for patients,
healthcare providers and insur-
ance companies. Randomized data
on treatment of botulinum toxin
in chronic whiplash syndrome are
scarce. We conducted a rando-
mized, placebo-controlled clinical
trial to prove efﬁcacy of botulinum
toxin for neck pain in chronic
whiplash syndrome. Methods 40
patients with chronic whiplash
syndrome (whiplash associated
disorders grade 1 and 2) were
randomly assigned to receive bo-
tulinum toxin (maximum 100
units) or placebo (saline) in
muscles with increased tender-
ness. Results After 12 weeks there
was no signiﬁcant difference be-
tween the two treatment groups in
decrease of neck pain intensity on
VAS ()7.0 mm, 95% conﬁdence
interval (CI) [)20.7 to +6.7]),
mean number of neck pain days
()1%; 95% CI [–15% to +13%]),
neck pain hours per day ()0.14;
95% CI [–3.0 to +2.7]), days on
which symptomatic treatment was
taken ()0.7%; 95% CI [–15% to
+13%]) number of analgesics ta-
ken per day ()0.14; 95% CI [–0.6
to +0.4]) and total cervical range
of motion ()11 degrees; 95% CI
)40 to +17]). There also was no
signiﬁcant difference in patient’s
assessment of improvement after
week 4, 8 and 12. Conclusions
Botulinum toxin was not proven
effective in treatment of neck pain
in chronic whiplash syndrome.
Increased muscle tenderness alone
might not be the major cause of
neck pain in whiplash syndrome.
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The Hague, The Netherlandscontrolled trial involving 26 patients with chronic
neck complaints after whiplash injury a signiﬁcant
improvement on total pain was suggested [7, 8].This
study however has some methodological problems,
such as a relatively short follow-up period of 4 weeks
and a small sample size [7, 8]. Based upon the present
evidence botulinum toxin cannot be recommended as
standard treatment for chronic neck pain after whi-
plash injury.
We therefore conducted a double blind placebo-
controlled randomized trial to conﬁrm if botulinum
toxin in treatment of neck pain is indeed effective in
chronic whiplash syndrome.
Methods
j Patients
Patients were eligible if they had a whiplash type neck distortion
deﬁned as a soft tissue injury of the neck following a vehicle colli-
sion, with symptoms lasting longer than 6 months. They also met
criteria of the Quebec Task Force grade 1 or 2 whiplash-associated
disorders (WAD). WAD grade 1 means only neck pain and stiffness
and grade 2 requires also musculoskeletal signs, e.g. a decreased
range of motion [24]. Exclusion criteria were: age < 18; pregnancy;
neuromuscular disorders; previous use of other investigational new
drugs in the past 30 days prior to the screening visit; previous use of
botulinum toxin; traumatic abnormalities on radiological ex-
aminations. The institutional ethics committee approved the study
protocol, and patients gave informed consent before inclusion.
j Study design
The trial had a double-blind, placebo-controlled parallel design.
After patient’s consent was obtained, we recorded demographics
(age, gender). During a baseline-period of 4 weeks, patients used
a diary to record the presence of neck pain, number of neck pain
hours per day, number of days on which medication was taken,
and number of tablets taken per day. At the end of this baseline-
period (week 0) patients recorded their mean neck pain intensity
scored on 100 mm Visual Analogue Scale of the previous 4 weeks
(week –4 to 0, VAS-pre-treatment). At week 0, patients were
randomly assigned to receive 100 units botulinum toxin (Botox)
or placebo (saline) in 2 cc syringes. At 12 weeks follow-up they
recorded again their mean neck pain intensity of the previous
12 weeks (week 0 to 12, VAS-post-treatment). The local trial
pharmacist prepared the drug, coded the syringes, and kept
treatment codes. The pharmacist had no further participation in
the trial. An experienced clinical neurophysiologist (D.T.) per-
formed all injections. Injection sites were selected individually (i.e.
 follow the pain’ approach) in muscles with clinically increased
muscle tone or muscle tenderness, and included m. occipito-
frontalis, m.temporalis, m. masseter, m. sternocleidomastoideus,
m. splenius capitis, m. trapezius and m. semispinalis.
j Outcomes
After patients were injected at week 0 in one single treatment-
session, clinical characteristics were recorded using diaries during
the 12 weeks post-treatment. The primary outcome measure was
the intensity of the neck pain of the total study period, week 0–12,
scored on the VAS at week 12 (one single measurement) compared
with baseline (VAS week –4 to 0). Patients were asked to rate (in a
single value) severity of neck pain which at times may be mild and
perhaps at others severe, by ‘‘integrating severity over time’’.
Secondary outcome measures were average number of neck
pain days, average number of neck pain hours per day, average
number of days on which symptomatic treatment was taken, mean
number of symptomatic tablets per day at 12 weeks compared with
baseline. Additionally, a blinded investigator asked patients whe-
ther there was any improvement in their condition after 4, 8 and
12 weeks in the two treatment groups (ﬁve-point scale: great wor-
sening, any worsening, no improvement, any improvement and
great improvement). Range of cervical motion was measured with a
cervical range of motion (CROM) device to measure the six con-
ventional movements of the spine at week 12 compared with
baseline. For measurements of CROM, the patients were seated in a
chair with their shoulders supported on a backrest. Patients were
instructed to assume a comfortable position and then to perform
each required movement and return to the start position. The
movements were assessed in this order: right rotation, left rotation,
right ﬂexion, left ﬂexion, extension, ﬂexion and then summated to
determine the mean total range of motion.
We also divided all patients in responders and non-responders
at week 12. We considered at least 45% reduction in the VAS
compared with baseline to be clinically relevant (e.g. responder).
All adverse events during the 3 months follow-up were recorded by
the investigators.
j Sample size determination
At baseline we expected mean neck pain intensity on the VAS of 40/
100 mm. The estimated placebo effect was a 8 mm reduction to a
VAS intensity of 32/100 at 12 weeks. We hypothesized a 18 mm
reduction in the treatment group to a VAS intensity of 22/100,
although there are no earlier data on treatment effect of BTX in
these patients. To detect this clinically relevant effect (8 versus
18 mm improvement) at a 5% level of statistical signiﬁcance (two-
tailed), with a power of 80%, a total of 40 patients was needed.
j Statistical analysis
We calculated mean differences between baseline VAS data and
VAS data after 12 weeks, using the t-test; statistical uncertainty was
expressed in 95% conﬁdence intervals. The responders at week 12
in each treatment group and the differences in improvement scores
were compared by use of the Chi-square test. All these analysis
were done with SPSS (version 10.0).
Results
Between November 1999 and March 2003 40 patients
were included at Leyenburg hospital The Hague. Of
the 59 patients assessed for eligibility, 19 patients
were excluded. Four patients did not meet the inclu-
sion criteria, eight patients refused to participate and
seven patients withdrew in the baseline period. No
patient was lost to follow-up.
In 1 patient the neck pain diary was incomplete
during the whole study period (missing data on neck
pain duration, days on which medication was taken
and mean number of tablets per day). In 7 patients the
neck pain diary for the post-treatment period was
291partly incomplete (missing data on neck pain dura-
tion, days on which medication was taken and mean
number of tablets per day). There were no differences
in baseline characteristics between the two treatment
groups. Neck pain intensity, VAS at baseline was
64.5 mm (SD = 14.8) in the botulinum group and
62.1 (SD = 20.3) in the placebo group (Table 1).
At 12 weeks the VAS scores were 52.0 mm
(SD = 29.2) in the botulinum group and 56.7 mm
(SD = 29.6) in the placebo group. Mean differences
between VAS pre- and post-treatment was 12.5 in the
botulinum group and 5.5 in the placebo group. The
therapeutic gain ( = difference in improvement be-
tween the two treatment groups measured in mm) was
–7.0 (p = 0.31; 95% CI (–20.7 to + 6.7)). Six patients
in the botulinum group were responders as deﬁned,
versus four in the placebo group (NS, p = 0.5).
Patients’ assessment of improvement/worsening
showed no signiﬁcant difference between the two
groups at week 4 (p = 0.9), week 8 (p = 0.4) and 12
(p = 0.4) (Table 2).
There were no signiﬁcant differences between the
two treatment groups in mean number of neck pain
days, mean number of neck pain hours per day, mean
number of days on which medication was taken, and
mean number of tablets taken per day pre- and post-
treatment (Table 3).
At baseline all patients showed a reduced cervical
range of motion (CROM) in all directions [9]. There
was a slight improvement in total CROM in favour of
the botulinum group. However, CROM was not sig-
niﬁcantly different between BTX group and placebo,
nor between responders and non-responders.
Twenty-seven patients reported minor side-effects,
15 in the botulinum toxin group and 12 in the placebo
group. The main complaint was ‘‘short-lasting pain at
the injection sites’’.
Discussion
Our study could not demonstrate botulinum toxin to
be more effective than placebo in treatment of neck
pain in patients with chronic whiplash syndrome.
Previous open label studies with botulinum toxin
in patients with chronic whiplash syndrome suggested
some beneﬁcial effect on neck pain [12]. Our study is
the second published randomized-controlled trial to
determine efﬁcacy of botulinum toxin in patients with
chronic whiplash syndrome. The other randomized
placebo-controlled trial in 26 patients with chronic
whiplash syndrome reported a beneﬁcial effect of
botulinum toxin [7, 8].
This study, however, has some methodological
shortcomings. Primary outcome was improvement of
headache intensity scored on the VAS after 4 weeks
compared with baseline. The post treatment differ-
ence between the two treatment groups was reported
to be signiﬁcant. However, baseline-characteristics
were signiﬁcantly different, with a signiﬁcant higher
headache intensity in the botulinum group at base-
line. (VAS 6.5 (range 2–9) versus 3.0 (0–8) in the
placebo group (p < 0.01)). The reported improve-
ment may mainly have been caused by the unequal
distribution of the patients at baseline. In their second
publication ( on the same trial) the mean total pain
score was reported, ranging from 0–30, expressing the
total pain experience for neck pain, headache and
shoulder pain. After 4 weeks the mean total pain was
10.0 (SE 1.3) in the botulinum group and 14.1(SE 21)
in the placebo group, which was also reported to be
signiﬁcant. These data are difﬁcult to interpret with-
out individual scores. Calculation of the standard
deviation could suggest that some patients even had a
negative mean total pain score. In any case, the dis-
tribution was truncated and skew to the right.
There are some points of discussion in our study.
We used injections at trigger points on an individual
basis, instead of following a standardized protocol.
This might seem subjective and arbitrary, but re-
sembles clinical practice and is usually recommended
for botulinum toxin (BTX) treatment in pain syn-
dromes [10, 16]. We used doses of 100 U Botox,
which should be sufﬁcient for a single treatment
session. There was only slight, not signiﬁcant, im-
provement of cervical range of motion in the botuli-
num group, suggesting some, if any, effect on muscle
tenderness. Also, none of our patients reported
muscular weakness as a side effect. Therefore, further
increase of the dosage of botulinum toxin might be
possible. There is some evidence that multiple treat-
ment sessions are needed for sufﬁcient clinical beneﬁt
[20]. In our study there was not even a trend for a
positive treatment effect after this single treatment
session of BTX. Still, a positive effect of multiple
treatment injections cannot be entirely ruled out [16].
Pathophysiology of chronic pain in whiplash syn-
drome is still a matter of debate. There is evidence
that myofascial pain is a major factor in chronic pain
syndromes like chronic neck pain and chronic ten-
sion-type headache [14]. The hypothesis of BTX being
effective in chronic whiplash syndrome could be pain
reduction by decreasing muscle tenderness and/or
activity. If increased muscle tenderness is a key fea-
ture in chronic neck pain after a whiplash injury, a
more beneﬁcial effect of BTX would have been ex-
pected. However, in other chronic pain syndromes
where muscle tenderness is thought to play a role BTX
was also proven ineffective [17, 23]. BTX might only
be effective in neck pain in combination with cervical
dystonia [26]. In our study were no patients with
cervical dystonia.
292Patients with chronic whiplash syndrome also
form a very heterogeneous group, with a wide spec-
trum of symptoms, varying from neck pain to head-
ache, with pain of different degrees. Many different
factors seem to play a role in the development of acute
and chronic pain after a whiplash injury.
There is ample evidence that central mechanisms
might play a more important role in the development
of chronic neck pain in whiplash patients [4], as
in other chronic pain syndromes. Damaged
peripheral tissue releases inﬂammatory mediators
(like bradykinine and prostaglandins) that changes
Table 1 Baseline characteristics
Characteristic Botulinum toxin (n = 20) Placebo (n = 20)
Mean age, years (range) 39 (20–58) 34 (20–49)
Female sex (%) 14 (70%) 13 (65%)
Ongoing claims 15 (75%) 18 (90%)
Mean duration of pain, months (SD) 40 (71) 37 (20)
Neck pain severity, mean VAS (SD) 64.5 (14.8) 62.1 (20.3)
Mean number of neck pain days, % (SD) 97% (11) *
1 96% (12)
Mean neck pain duration per day, hours (SD) 12.7 (4.0) *
3 11.7 (4.5)
Mean number of medication days, % (SD) 50% (41) *
1 36% (40)
Mean number of analgesics per day, tablets (SD) 1.4 (1.9) 1.3 (2.1)
Mean total cervical range of motion, degrees (SD) 266 (73) *
1 266 (60) *
1
*
1 = one missing data; *
3 = three missing data
Table 2 Improvement scale
Improvement
At 4 weeks At 8 weeks At 12 weeks
Botulinum toxin (n = 20) Placebo (n = 20) Botulinum toxin (n = 20) Placebo (n = 20) Botulinum toxin (n = 20) Placebo (n = 20)
Great worsening 40 02 12
Any worsening 24 14 23
No improvement 68 87 68
Any improvement 55 54 54
Great improvement 23 63 63
Total 19*
1 20 20 20 20 20
*
1 = one missing data
Table 3 Secondary outcome measures
Outcome Botulinum toxin (n = 20) Placebo (n = 20) Therapeutic gain (95% CI)
Neck pain days (% ± SD)
Baseline (4 weeks) 97% (11) *
1 96% (12)
Post-treatment (12 weeks) 89% (23) *
2 89% (25) *
2
Mean difference 8% (18) 7% (22) )1% ()15% to + 13%)
Neck pain duration (hours/day ± SD)
Baseline (4 weeks) 12.7 (4.0) *
3 11.7 (4.5)
Post-treatment (12 weeks) 12.2 (4.6) *
7 11.0 (5.1) *
2
Mean difference 0.86 (2.2) 0.72 (4.7) )0.14 ()3.0 to + 2.7)
Days on which analgesics were taken (% ± SD)
Baseline (4 weeks) 49% (42%) 35% (40%)
Post-treatment (12 weeks) 42% (38%) *
3 24% (32%) *
2
Mean difference 6.4% (16%) 5.7% (24%) 0.7% ()15% to + 13%)
Number of analgesics taken per day (tablets/day ± SD)
Baseline (4 weeks) 1.4 (1.9) *
1 1.3 (2.1)
Post-treatment (12 weeks) 1.2 (1.8) *
2 0.95 (1.9) *
1
Mean difference 0.32 (0.8) 0.18 (0.6) )0.14 ()0.6 to + 0.4)
Total cervical range of motion (degrees ± SD)
Baseline 266 (73) *
1 266 (60) *
1
Post-treatment (week 12) 293 (59) *
2 277 (62) *
3
Mean difference 22 (43) 11 (36) )11 ()40 to + 17)
*
1 = one missing data; *
2 = two missing data; *
3 = three missing data *
7 = seven missing data
293the sensitivity of high-threshold nociceptors (per-
ipheral sensitization). This, in turn, sets up changes in
the responsiveness of neurons in the central nervous
system (CNS), ultimately increasing the excitability
of neurons within the CNS, representing central
sensitization [21]. Patients with chronic whiplash
syndrome display exaggerated pain after sensory sti-
mulation as a consequence of this state of hyper-
excitability of the central nociceptive system [1, 13].
In other words, an alteration in function of the central
nervous system, the way it responds to normal inputs,
seems present in these patients.
This central hypersensivity is probably in-
dependent of the nociceptive input arising from the
painful and tender muscles [4], and possibly a con-
sequence of deﬁcient pain inhibitory systems.
Many somatic, psychological or cultural factors
may inﬂuence central sensitization. Different studies
show that prognosis of chronic whiplash syndrome is
also dependent on cultural factors [15, 18, 22]. It has
even been shown that presence or absence of com-
pensation claims is one of the most important pre-
dictors of bad outcome in patients after whiplash
injury (also present in our group in 75–90% of the
patients) [11, 19]. The etiological contribution of all
different psychological factors, like for example cop-
ing style [3], to central sensitization is not yet clar-
iﬁed. It is not to be predicted that BTX will improve
all different factors, especially psychological and cul-
tural factors, which may contribute to development of
this chronic whiplash syndrome.
Based on present evidence BTX cannot be re-
commended as treatment for neck pain in chronic
whiplash patients. Future studies directed on possible
central mechanisms of this complicated chronic pain
syndrome are warranted.
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